Drug Price Trends for NIFEDIPINE ER

Average Pharmacy Cost for NIFEDIPINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
NIFEDIPINE ER 30 MG TABLET	50742-0260-01	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	24979-0011-12	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	50268-0597-15	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	00904-7208-06	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	50268-0597-11	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	00904-7208-61	0.11652	EACH	2025-04-23
NIFEDIPINE ER 30 MG TABLET	24979-0011-01	0.11652	EACH	2025-04-23

Nifedipine ER Market Analysis and Price Projections

Introduction to Nifedipine ER

Nifedipine ER, or extended-release nifedipine, is a calcium channel blocker used primarily to treat hypertension, angina pectoris, and other heart-related conditions. It works by relaxing and expanding blood vessels, thereby increasing blood flow and reducing the workload on the heart[1].

Market Size and Growth Projections

The global nifedipine medication market, which includes nifedipine ER, is anticipated to experience significant growth over the coming years. As of 2022, the market was valued at approximately $1,094.2 million and is projected to reach $1,936.9 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 9.4% during the forecast period of 2022-2030[1].

Market Drivers

Several factors are driving the growth of the nifedipine ER market:

Growing Prevalence of Hypertension

The increasing prevalence of hypertension is a major driver. Hypertension is a common condition that affects a significant portion of the global population, and nifedipine is commonly prescribed for its management[1].

Increasing Cardiovascular Diseases

The rise in cardiovascular diseases, including heart failure and angina, also contributes to the demand for nifedipine ER[1].

Growing Geriatric Population

The expanding geriatric population is another key factor, as older individuals are more prone to cardiovascular diseases and hypertension[1].

Expansion of Healthcare Infrastructure

Improvements in healthcare infrastructure and increasing healthcare expenditure globally are also boosting the market growth[1].

Market Segments

By Dosage Form

The extended-release tablets segment is expected to hold a dominant position in the market. These tablets work by slowly releasing the medication over a longer period, reducing the frequency of dosing and improving patient compliance[1].

By Indication

Hypertension is the leading indication for nifedipine ER, as it is widely prescribed for managing high blood pressure[1].

By Distribution Channel

Retail pharmacies are expected to dominate the distribution channel segment due to their wide shelf space for prescribed medications and easy accessibility for patients[1].

Regional Analysis

North America

North America is projected to hold a dominant position in the global nifedipine ER market, driven by the increasing prevalence of hypertension, growing healthcare expenditure, and the presence of a well-established healthcare sector[1][3].

Asia-Pacific

The Asia-Pacific region is expected to be the fastest-growing segment, driven by the increasing incidence of chronic diseases, an expanding older population, and improvements in healthcare infrastructure, particularly in countries like India and China[5].

Price Projections and Affordability

The cost of nifedipine ER can vary based on the dosage form, quantity, and pharmacy.

Extended-Release Tablets

For example, the cost for Procardia XL (a brand of nifedipine ER) 30 mg oral tablet, extended release, can range from $705 to $2,096 for a supply of 100 to 300 tablets, respectively[2].

Generic Versions

Generic versions of nifedipine ER are also available, which can be more affordable. For instance, the cost for a generic nifedipine 60 mg oral tablet, extended release, can start from around $92 for 180 tablets[4].

Market Opportunities

Shift Towards Combination Therapy

There is a growing preference towards combination therapies that include nifedipine ER and other antihypertensive drugs. This shift is expected to open new avenues for market growth as these combinations offer improved outcomes in managing hypertension[1].

Market Restraints

Side Effects and Safety Concerns

Long-term use of calcium channel blockers like nifedipine ER can be associated with side effects and safety concerns, which may hamper market growth. These concerns include potential interactions with other medications and adverse effects such as edema and dizziness[1].

Key Players

The global nifedipine ER market is competitive, with several key players operating in the space. These include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., and others[1].

Key Trends and Analysis

Increasing Healthcare Expenditure

Global healthcare expenditure has been on the rise, which is improving treatment processes and driving the demand for nifedipine ER. According to the World Health Organization, global health spending continually rose between 2000 and 2018 and reached $8.3 trillion or 10% of global GDP by 2018[1].

Impact of Chronic Diseases

The increasing incidence of chronic diseases such as obesity, which is linked to higher rates of hypertension and other cardiovascular conditions, is also a significant trend. For instance, in the United States, 41.9% of adults are obese, with higher rates among Black and Latino individuals[3].

"Global spending on health continually rose between 2000 and 2018 and reached US$ 8.3 trillion or 10% of global GDP by 2018" - World Health Organization[1].

Key Takeaways

• The global nifedipine ER market is expected to grow at a CAGR of 9.4% from 2022 to 2030.
• The market is driven by the growing prevalence of hypertension, increasing cardiovascular diseases, and expanding geriatric population.
• Extended-release tablets and hypertension management are dominant segments.
• North America is the largest market, while the Asia-Pacific region is the fastest-growing.
• Combination therapies and increasing healthcare expenditure are key trends.
• Side effects and safety concerns are significant restraints.

FAQs

1. What is nifedipine ER used for?

Nifedipine ER is used to treat hypertension, angina pectoris, and other heart-related conditions by relaxing and expanding blood vessels.

2. What is the projected market size of nifedipine ER by 2030?

The global nifedipine medication market, including nifedipine ER, is projected to reach $1,936.9 million by 2030[1].

3. What are the main drivers of the nifedipine ER market?

The main drivers include the growing prevalence of hypertension, increasing cardiovascular diseases, expanding geriatric population, and expansion of healthcare infrastructure[1].

4. Which region is expected to dominate the nifedipine ER market?

North America is expected to hold a dominant position in the global nifedipine ER market[1][3].

5. Are there any generic versions of nifedipine ER available?

Yes, generic versions of nifedipine ER are available and can be more affordable compared to brand-name versions[2][4].

Cited Sources:

1. Coherent Market Insights, "Nifedipine Medication Market to Hit US$ 1,936.9 Million Globally by 2030 at 9.4% CAGR", November 7, 2023.
2. Drugs.com, "Procardia XL Prices, Coupons, Copay Cards & Patient Assistance".
3. StraitsResearch, "Nifedipine Market Size, Share, Trends, Forecast Report 2032", February 13, 2024.
4. Drugs.com, "Nifedipine Prices, Coupons, Copay Cards & Patient Assistance".
5. IndustryARC, "Nifedipine Market Size Report, 2022-2027".

Last updated: 2025-01-07